- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07570316
A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease (VitaliThy)
A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease Inadequately Controlled With Antithyroid Drugs
The main purpose of this study is to look at how efgartigimod affects thyroid function in adults with Graves' Disease (GD). The study will also check whether efgartigimod is safe and well tolerated. It will look at how efgartigimod is distributed and eliminated in the body, how it changes antibody levels, and how the immune system responds to it.
The study consists of a part A double-blinded treatment period, a part B treatment/observation period and a part C open-label treatment/observation period. During the part A and part B treatment periods, participants will receive efgartigimod PH20 SC via Prefilled Syringe (PFS) or placebo. During the part C open-label treatment period, participants will receive efgartigimod PH20 SC PFS. Participation in the different parts of the study will depend on the participant's response to treatment.
The total study duration for participants ranges from 63 to 135 weeks, depending on the response to treatment.
More information can be found here: https://clinicaltrials.argenx.com/vitalithy
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Phase
- Phase 3
Contacts et emplacements
Coordonnées de l'étude
- Nom: Sabine Coppieters, MD
- Numéro de téléphone: 857-350-4834
- E-mail: clinicaltrials@argenx.com
Lieux d'étude
-
-
-
Tbilisi, Géorgie, 0114
- Recrutement
- New Hospitals
-
Contact:
- Lia Katcharava, MD
- Numéro de téléphone: +995 599530278
- E-mail: likakatcharava@yahoo.com
-
Tbilisi, Géorgie, 0102
- Recrutement
- LLC American Hospital Network
-
Contact:
- Nino Gabidzashvili, MD
- E-mail: endo.advice@gmail.com
-
Tbilisi, Géorgie, 0119
- Recrutement
- LLC Todua Clinic
-
Contact:
- Tamar Khutsishvili, MD
- E-mail: Khutsishvilitamar1@outlook.com
-
Tbilisi, Géorgie, 0112
- Recrutement
- LTD Israeli-Georgian Medical Research Clinic Healthycore
-
Contact:
- Miranda Baratashvili, MD
- E-mail: baratashvilimiranda@gmail.com
-
Tbilisi, Géorgie, 0159
- Recrutement
- In Vitro Fertilization Center LLC
-
Contact:
- Tea Khurodze, MD
- E-mail: khurodze@yahoo.com
-
-
-
-
Tyne and Wear
-
Gateshead, Tyne and Wear, Royaume-Uni, NE9 6SX
- Recrutement
- Queen Elizabeth Hospital (Gateshead Health NHS Foundation Trust)
-
Contact:
- Syed Salman Razvi
- Numéro de téléphone: +44 191 445 6052
- E-mail: salman.razvi@newcastle.ac.uk
-
-
-
-
California
-
Carlsbad, California, États-Unis, 92012
- Recrutement
- Profound Research LLC at Tri-City Primary Care
-
Contact:
- Jamil Alkhaddo, MD
- Numéro de téléphone: 419-681-0637
- E-mail: jamil.alkhaddo@profoundresearch.com
-
Orange, California, États-Unis, 92868
- Recrutement
- Diabetes Associates Medical Group
-
Contact:
- Ivy-Joan Madu, MD
- Numéro de téléphone: 714-202-8894
- E-mail: diabetesmd@sbcglobal.net
-
Pasadena, California, États-Unis, 91101
- Recrutement
- Pasadena Clinical Trials
-
Contact:
- Tzu-Jen Tzao
- Numéro de téléphone: 5206127860
- E-mail: ttzao@pasadenatrials.com
-
Pasadena, California, États-Unis, 91105
- Recrutement
- Havana Research Institute LLC.
-
Contact:
- John De Beixedon, MD
- Numéro de téléphone: 626-698-9794
- E-mail: drjohn@havanaresearchinstitute.com
-
San Jose, California, États-Unis, 95128
- Recrutement
- San Jose Clinical Trials
-
Contact:
- Richard Cherlin
- Numéro de téléphone: 408-358-2663
- E-mail: rcherlin@sanjosetrials.com
-
-
Florida
-
Fleming Island, Florida, États-Unis, 32003
- Recrutement
- Northeast Florida Endocrine & Diabetes Associates (NEFEDA) - Orange Park Location
-
Contact:
- Senan Sultan, MD
- Numéro de téléphone: 478-319-7900
- E-mail: drsultan@nerifl.com
-
Fort Lauderdale, Florida, États-Unis, 33312
- Recrutement
- The Center for Diabetes and Endocrine Care
-
Contact:
- Sam Lerman, MD
- Numéro de téléphone: 954-963-7100
- E-mail: slerman@diabetes-endocare.com
-
Jacksonville, Florida, États-Unis, 32256
- Recrutement
- University of Florida Jacksonville College of Medicine
-
Contact:
- Christian Koch
- Numéro de téléphone: +1 857-350-4834
- E-mail: Christian.Koch@jax.ufl.edu
-
Kissimmee, Florida, États-Unis, 34744
- Recrutement
- Ilumina Medical Research LLC
-
Contact:
- Max Sosa-Pagan, MD
- Numéro de téléphone: 857-350-4834
- E-mail: MSosapaganMD@gmail.com
-
Miami, Florida, États-Unis, 33144
- Recrutement
- Oceane 7 Medical & Research Center, Inc
-
Contact:
- Orlando Fernandez
- Numéro de téléphone: 305 261 2738
- E-mail: o.fernandez.oceane7@gmail.com
-
-
Kansas
-
Lenexa, Kansas, États-Unis, 66219
- Recrutement
- Johnson County Clin-Trials, Inc.
-
Contact:
- Thomas Kreamer, MD
- Numéro de téléphone: 913-825-4400
- E-mail: tkreamer@jcct.com
-
Wichita, Kansas, États-Unis, 67226
- Recrutement
- Alliance for Multispecialty Research, LLC
-
Contact:
- Terry Klein
- Numéro de téléphone: 316-689-6629
- E-mail: terry.klein@amr-clinical.com
-
-
Michigan
-
Ann Arbor, Michigan, États-Unis, 48109
- Recrutement
- University of Michigan
-
Contact:
- Tae-Hwa Chun
- Numéro de téléphone: 734-615-5420
- E-mail: taehwa@med.umich.edu
-
Dearborn, Michigan, États-Unis, 48126
- Recrutement
- Metro Detroit Endocrinology Center
-
Contact:
- Ayman Elkadry, MD
- Numéro de téléphone: 313-203-5300
- E-mail: aymankad73@gmail.com
-
Farmington Hills, Michigan, États-Unis, 48334
- Recrutement
- Profound Research
-
Contact:
- Gary Edelson, MD
- Numéro de téléphone: 947-254-1920
- E-mail: gary.edelson@profoundresearch.io
-
-
Missouri
-
Kansas City, Missouri, États-Unis, 64108
- Recrutement
- Truman Medical Center
-
Contact:
- Rajib Bhattacharya, MD
- Numéro de téléphone: +1 857-350-4834
- E-mail: rajib.bhattacharya@uhkc.org
-
-
New York
-
Albany, New York, États-Unis, 12203
- Recrutement
- Albany Medical College Community Endocrinology
-
Contact:
- Robert Busch
- Numéro de téléphone: 518 489 4704
- E-mail: thyroiddoc@aol.com
-
New York, New York, États-Unis, 10016
- Recrutement
- Endocrine Associates of West Village PC
-
Contact:
- Anastasios Manessis, MD
- Numéro de téléphone: 646-660-9991
- E-mail: amanessis@endocrinenyc.com
-
-
North Carolina
-
Asheville, North Carolina, États-Unis, 28803
- Recrutement
- Asheville Clinical Research
-
Contact:
- Lauren Bernstein
- Numéro de téléphone: +1 857-350-4834
- E-mail: bbernstein@ashevilleclinicaltrials.com
-
Raleigh, North Carolina, États-Unis, 27612
- Recrutement
- Wake Internal Medicine Consultants
-
Contact:
- Juman Takeddin, MD
- Numéro de téléphone: 919-781-7500
- E-mail: jtakeddin@wakeinternalmedicine.com
-
-
Texas
-
Dallas, Texas, États-Unis, 75231
- Recrutement
- Research Institute of Dallas
-
Contact:
- Heidi Shea, MD
- Numéro de téléphone: 927-867-4658
- E-mail: hshea@eadallas.com
-
El Paso, Texas, États-Unis, 79935
- Recrutement
- Frontier Medical Center - Academy of Diabetes Thyroid and Endocrine
-
Contact:
- Sergio Rovner
- Numéro de téléphone: 915-633-9387
- E-mail: sergiorovner@hotmail.com
-
Houston, Texas, États-Unis, 77040
- Recrutement
- Juno Research
-
Contact:
- Damaris Vega, MD
- Numéro de téléphone: 713-779-5494
- E-mail: Dvega@jcct.com
-
Houston, Texas, États-Unis, 77089
- Recrutement
- Clinic of Endocrinology
-
Contact:
- Amir Hassan, MD
- Numéro de téléphone: 281-944-3610
- E-mail: amir@biopharmainfo.net
-
Irving, Texas, États-Unis, 75039
- Recrutement
- Tekton Research Irving
-
Contact:
- Pablo Mora, MD
- Numéro de téléphone: 972-566-7799
- E-mail: pablo.mora@tektonresearch.com
-
McAllen, Texas, États-Unis, 78503
- Recrutement
- Biopharma Informatic, LLC
-
Contact:
- Gloria Ortiz, MD
- Numéro de téléphone: 281-944-3610
- E-mail: gortiz@biopharmainfo.net
-
McKinney, Texas, États-Unis, 75069
- Recrutement
- Tekton Research - McKinney
-
Contact:
- Muhammad Siddiqui, MD
- Numéro de téléphone: 972-777-6011
- E-mail: muhammad.siddiqui@tektonresearch.com
-
Mesquite, Texas, États-Unis, 75149
- Recrutement
- Southern Endocrinology Associates PA
-
Contact:
- Sumana Gangi, MD
- Numéro de téléphone: 214-909-8904
- E-mail: sumana_gangi@yahoo.com
-
Shavano Park, Texas, États-Unis, 78231
- Recrutement
- Consano Clinical Research
-
Contact:
- Daniel Katselnik, MD
- Numéro de téléphone: 210-545-4900
- E-mail: katselnik.md@consanosa.com
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Is at least 18 years of age and the local legal age of consent for clinical studies when signing the ICF.
- Has a documented diagnosis of GD with TRAb (anti-thyrotropin receptor antibody) levels >=ULN (upper limit of normal) at screening.
- Has active hyperthyroidism due to GD with TSH (thyroid-stimulating hormone) <0.1 mIU/L at screening.
- Has been treated with MMI (methimazole) or CBZ (carbimazole) for at least 3 months before screening.
Exclusion Criteria:
- History of hyperthyroidism not caused by GD (eg, toxic adenoma or toxic multinodular goiter).
- History of RAI (radioactive iodine) therapy or received a total thyroidectomy.
- T3- or T4-containing medication or supplement (eg, levothyroxine, liothyronine, desiccated thyroid preparations, or thyroid-support supplements) received <6 weeks before screening.
- Any complication of hyperthyroidism or underlying medical condition that would put the participant at undue risk. This includes arrhythmia or tachyarrhythmia related to GD, such as atrial fibrillation or atrial flutter not sufficiently controlled with medications.
- Graves' orbitopathy/Thyroid Eye Disease (GO/TED) requiring systemic therapy (eg, corticosteroids), orbital injections, orbital surgery, or orbital radiation, or expected immediate surgical intervention and/or planned corrective surgery/irradiation or medical therapy during the study.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Quadruple
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Part A - efgartigimod PH20 SC PFS
Participants will receive efgartigimod PH20 SC Via Prefilled Syringe (PFS) during the part A double-blinded treatment period. |
Subcutaneous injection of Efgartigimod PH20 Via Prefilled Syringe (PFS) |
|
Comparateur placebo: Part A - placebo PH20 SC PFS
Participants will receive placebo PH20 SC Via Prefilled Syringe (PFS) during the part A double-blinded treatment period. |
Subcutaneous injection of placebo PH20 via Prefilled Syringe (PFS) |
|
Expérimental: Part B - efgartigimod PH20 SC PFS
Participants will receive efgartigimod PH20 SC Via Prefilled Syringe (PFS) during the part B treatment period. |
Subcutaneous injection of Efgartigimod PH20 Via Prefilled Syringe (PFS) |
|
Expérimental: Part B - placebo PH20 SC PFS
Participants will receive placebo PH20 SC Via Prefilled Syringe (PFS) during the part B treatment period. |
Subcutaneous injection of placebo PH20 via Prefilled Syringe (PFS) |
|
Expérimental: Part C - efgartigimod PH20 SC PFS
Participants will receive efgartigimod PH20 SC PFS in the part C open-label treatment period |
Subcutaneous injection of Efgartigimod PH20 Via Prefilled Syringe (PFS) |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Percentage of participants who are euthyroid (fT3, fT4, and TSH within normal ranges) off ATDs at week 24 in part A
Délai: Up to 24 weeks (part A)
|
Free triiodothyronine: [fT3]; free thyroxine: [fT4]; ATDs: antithyroid drugs |
Up to 24 weeks (part A)
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Time to becoming euthyroid
Délai: Up to 24 weeks (part A) + up to 135 weeks
|
Up to 24 weeks (part A) + up to 135 weeks
|
|
|
Efgartigimod serum concentrations over time
Délai: Up to 24 weeks (part A) + 72 weeks (part C)
|
Up to 24 weeks (part A) + 72 weeks (part C)
|
|
|
Time to becoming euthyroid off ATDs in part A
Délai: Up to 24 weeks (part A)
|
ATDs: antithyroid drugs |
Up to 24 weeks (part A)
|
|
Percentage of participants who are euthyroid and receiving MMI ≤5 mg/day or CBZ ≤7.5 mg/day at week 24 in part A
Délai: Up to 24 weeks (part A)
|
MMI: methimazole (also known as thiamazole); CBZ: carbimazole. |
Up to 24 weeks (part A)
|
|
Percentage of participants with fT3 and fT4 levels below the ULN off ATDs at week 24 in part A
Délai: Up to 24 weeks (part A)
|
ULN : upper limit of normal; ATDs: antithyroid drugs. |
Up to 24 weeks (part A)
|
|
Percentage of participants who are euthyroid off ATDs and TRAb seronegative at week 24 in part A
Délai: Up to 24 weeks (part A)
|
TRAb: anti-TSHR autoantibodies; ATDs: antithyroid drugs. |
Up to 24 weeks (part A)
|
|
Time to becoming euthyroid off ATDs and TRAb seronegative
Délai: Up to 24 weeks (part A) + up to 135 weeks
|
ATDs: antithyroid drugs; TRAb: anti-TSHR autoantibodies. |
Up to 24 weeks (part A) + up to 135 weeks
|
|
Time to becoming euthyroid and receiving an ATD dose of MMI ≤5 mg/day or CBZ ≤7.5 mg/day (part A)
Délai: Up to 24 weeks (Part A)
|
ATDs: antithyroid drugs; MMI: methimazole (also known as thiamazole); CBZ: carbimazole. |
Up to 24 weeks (Part A)
|
|
Time to having TSH within normal ranges among participants who have TSH lower than the LLN at baseline (part A)
Délai: Up to 24 weeks (part A)
|
TSH: thyroid-stimulating hormone; LLN: lower limit of normal. |
Up to 24 weeks (part A)
|
|
Percentage of participants who remain euthyroid without ATDs
Délai: Up to 74 weeks (part B)
|
ATDs: antithyroid drug |
Up to 74 weeks (part B)
|
|
Percentage of participants who remain euthyroid without ATDs and without efgartigimod PH20 SC PFS for 6, 12, and 18 months
Délai: Up to 74 weeks (part B) + up to 135 weeks
|
ATDs: antithyroid drug |
Up to 74 weeks (part B) + up to 135 weeks
|
|
Percentage of participants who remain euthyroid without ATDs and without efgartigimod PH20 SC PFS
Délai: Up to 72 weeks (part C)
|
ATDs: antithyroid drug |
Up to 72 weeks (part C)
|
|
Incidence of AEs and SAEs
Délai: Up to 135 weeks
|
AEs: adverse events ; SAEs: serious adverse events. |
Up to 135 weeks
|
|
Change in ThyPRO-39 over time
Délai: Up to 135 weeks
|
The Thyroid-Specific Patient-Reported Outcome Short Form (ThyPRO-39) 39 item version of the ThyPRO. Each item is related to a specific aspect of the participant's experience with their thyroid condition. Each item is scored on a 5-point Likert scale, and the scores are then transformed to a 0-to-100 scale. Higher scores indicate worse health status. |
Up to 135 weeks
|
|
Change in PROMIS-PF10a over time
Délai: Up to 135 weeks
|
The Patient-Reported Outcomes Measurement Information System Physical Function-10 item (PROMIS-PF10a) is a self-administered physical functioning assessment comprising 10 items that measure respondents' ability to perform common physical tasks. Scoring involves summing the numerical responses to each item; higher scores indicate better physical function. |
Up to 135 weeks
|
|
Percentage change from baseline in total IgG levels in serum over time
Délai: Up to 98 weeks
|
IgG: immunoglobulin G |
Up to 98 weeks
|
|
Percentage change from baseline in TRAb serum levels over time
Délai: Up to 135 weeks
|
TRAb: anti-TSHR autoantibodies. |
Up to 135 weeks
|
|
Incidence of ADA against efgartigimod in serum
Délai: Up to 24 weeks (part A) + up to 135 weeks
|
ADA: antidrug antibody(ies) |
Up to 24 weeks (part A) + up to 135 weeks
|
|
Incidence of antibodies against rHuPH20 in plasma
Délai: Up to 24 weeks (part A) + Up to 135 weeks
|
rHuPH20: recombinant human hyaluronidase PH20 |
Up to 24 weeks (part A) + Up to 135 weeks
|
|
Incidence of NAb against efgartigimod in serum and rHuPH20 in plasma
Délai: Up to 24 weeks (part A) + up to 135 weeks
|
NAb: neutralizing antibody(ies); rHuPH20: recombinant human hyaluronidase PH20. |
Up to 24 weeks (part A) + up to 135 weeks
|
Collaborateurs et enquêteurs
Parrainer
Publications et liens utiles
Liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- ARGX-113-25-GRD-3002
- 2025-524223-42-00 (Ctis)
- 2025 (Subvention/contrat des NIH des États-Unis)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .